Abstract: Objective: Evaluate the short-term results of neoadjuvant endocrine therapy (NET) for postmenopausal breast cancer patients and correlation to clinicopathologic factors.Methods: 32 cases of postmenopausal breast cancer with stage Ⅱ and Ⅲ treated with letrozole for 4 months.Result: Clinical OR(cCR=CR+PR) is 70% in 29 cases with ER(+) and/or PR(+).Sonography OR is 55%.The response of three patients with ER and PR-negative is SD.Pathological response: slight response is 11 cases (79%),remarkable response is 2 cases(14%) ,special response is 1 case (7%) without pCR. The cOR of lower histological grade is higher (P<0.05). The OR with ER and PR both possitive and ER strong possitive (++) is highest. There are no correlation found between response and the expression of HER-2.Only 13% of patients experienced grade adverse events . 4 cases (29%) treated with BCS and 10 cases with mastectom among 14 cases received surgical treatment after NET. Conclusion: NET with letrozole as a treatment option for postmenopausal patients with receptor-positive breast cancer is effective and safe ,especially for olderly women whom cannot tolerate the toxicities of chemotherapy and/or concomitant with with some serious diseases who are not eligible for radical mastactomy.